MetaCap

Zymeworks Inc. (ZYME)

NASDAQ: ZYMEHealth CareBiotechnology: Pharmaceutical PreparationsUSD

26.14-0.72 (-2.68%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ZYME stock chart

Technical analysis

Key statistics

All statistics
52-week range
21.52 – 31.97
Day range
26.09 – 27.56
Volume / Avg
738.81K / 1.09M
Beta
—

52-week range

$21.52$31.97

ZYME stock today

On Nov 20, ZYME ended the session at $26.14, shedding $0.72 (2.68%), versus the S&P 500's 3.70% decline. Shares are 18.2% below their 52-week high of $31.97, set on Nov 10, 2026 and 21.5% above the 52-week low of $21.52, in the middle of the past year's range. ZYME is down 0.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 8.8%.

Zymeworks trades at 49.3x its trailing twelve-month earnings per share of $0.53. Its forward P/E of 55.0x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Zymeworks

Company profile

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Kenneth H. Galbraith C.A.
Headquarters
Middletown, DE
Employees
279

Financial highlights

Full financials

In fiscal 2025, Zymeworks generated $106.0 million in revenue, up 38.9% from fiscal 2024, its 2nd consecutive year of revenue growth. Zymeworks reported a net loss of $81.1 million, compared with a loss of $122.7 million a year earlier. Operating margin was -87.3%.

Zymeworks annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$105.97M$76.30M$76.01M$412.48M$26.68M
Growth+38.87%+0.38%-81.57%+1446.03%-31.50%
Net income$-81.13M$-122.69M$-118.67M$124.34M$-211.84M
EPS (diluted)$-1.08$-1.62$-1.72$1.90$-4.61

Analyst forecast

Forecast

Consensus (14 analysts)

strong_buy

Avg. price target

$43.29+65.61%

  • Strong buy 2
  • Buy 12
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $35.00High $60.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.26 vs $2.40
Surprise
-110.83%

ZYME news

All ZYME news

Zymeworks peers

Health Care sector
ZYME peer companies
CompanyPrice% ChgMarket capCompare
MRVIMaravai LifeSciences Holdings Inc. Class A6.98-2.92%$1.81Bvs ZYME
SEPNSepterna Inc.38.61-1.51%$1.84Bvs ZYME
VERAVera Therapeutics Inc. Class A25.45-4.86%$1.84Bvs ZYME
IMNMImmunome Inc.15.69-5.54%$1.85Bvs ZYME
ETONEton Pharmaceuticals Inc.60.85-0.83%$1.76Bvs ZYME
STOKStoke Therapeutics Inc.26.81-0.45%$1.75Bvs ZYME
TRAXFirst Tracks Biotherapeutics Inc.41.64-6.34%$1.75Bvs ZYME
BHVNBiohaven Ltd.12.39-9.23%$1.87Bvs ZYME

Indexes, lists and sector

Zymeworks stock FAQ

What is Zymeworks's stock price today?

ZYME last traded at $26.14 as of Nov 20, 4:00 PM EST, down 2.68% on the day. Prices are delayed at least 15 minutes.

What is ZYME's P/E ratio?

ZYME trades at a trailing P/E ratio of 49.32 and a forward P/E of 54.95.

Who is Zymeworks's CEO?

Mr. Kenneth H. Galbraith C.A. is the chief executive officer of Zymeworks Inc., which has about 279 employees.

What is the ZYME 52-week high?

The 52-week high for ZYME is $31.97 and the 52-week low is $21.52. The stock is currently 18.2% below its high.

Compare ZYME